Correlation Between Cadrenal Therapeutics, and Cue Biopharma
Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Cue Biopharma, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Cue Biopharma.
Diversification Opportunities for Cadrenal Therapeutics, and Cue Biopharma
0.74 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Cadrenal and Cue is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Cue Biopharma go up and down completely randomly.
Pair Corralation between Cadrenal Therapeutics, and Cue Biopharma
Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to generate 0.86 times more return on investment than Cue Biopharma. However, Cadrenal Therapeutics, Common is 1.16 times less risky than Cue Biopharma. It trades about -0.07 of its potential returns per unit of risk. Cue Biopharma is currently generating about -0.1 per unit of risk. If you would invest 1,760 in Cadrenal Therapeutics, Common on September 2, 2024 and sell it today you would lose (241.00) from holding Cadrenal Therapeutics, Common or give up 13.69% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cadrenal Therapeutics, Common vs. Cue Biopharma
Performance |
| Timeline |
| Cadrenal Therapeutics, |
| Cue Biopharma |
Cadrenal Therapeutics, and Cue Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cadrenal Therapeutics, and Cue Biopharma
The main advantage of trading using opposite Cadrenal Therapeutics, and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.The idea behind Cadrenal Therapeutics, Common and Cue Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
| Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Complementary Tools
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |